Tumor Heterogeneity: The Role of PET-CT

Investigating Tumor Heterogeneity through PET-CT Imaging

We have been exploring tumor heterogeneity primarily with the aid of PET-CT as a molecular imaging tool. This study is conducted across various conditions.

Professor Gligorov’s Case Study

Recently, Professor Gligorov discussed breast cancer and PET imaging. He presented an example of a patient with dual imaging: one using FDG (common molecule) and the other using fluorooestradiol or FES for ER-positive patients.

Impact of Dual Imaging

The results showed that an ER-positive patient, who tests positive for both PET FACE and PET FDG, responds well to targeted therapy when dealing with metastatic disease. However, if the same patient is scanned using F18 furosesterole, the imaging result may come back negative, causing treatment resistance.

The Importance of F18 in Molecular Profiling

This suggests that while molecular profiling is crucial, it’s also essential to confirm ER expression throughout the body by conducting an F18 scan before starting treatment.

Study Findings by Iqbal (2023)

A study done in 2023 compared ER-positive patients with metastatic disease and triple-negative patients using the same concept, providing valuable insights for further research.